Table 1.

Case reports of SLE during pregnancy with uterine wall thinning and PAS

Author,year	Age(y)	Parity	PSL duration(y)	PSL use during pregnancy	Risk factors of PAS	Obstetric complication	GA at labror(wk)	Induction labor	Delivery	Treatment	Amount of blood loss(ml)
Noh JJ et al., 2013 [2]	36	0	19	Yes	IVF	Rupture uterus	23	None	CS	Hysterectomy	NS
Tokushige Y et al., 2017 [3]	35	0	5	Yes	IVF	GH	39	Yes (Oxytocin)	CS	Hysterectomy	4500
Tomimatsu T et al., 2021 [4]	32	0	8	Yes	IVF	PE	35	Yes (Oxytocin)	CS	Hysterectomy	2200
Mittal N et al., 2018 [5]	36	2	9	Yes	Placenta previa	Placenta previa	36	None	CS	Hysterectomy	6000
Kim HM et al., 2020 [6]	33	0	10	Yes	None	Rupture uterus	34	None	CS	Hysterectomy	NS
Kim HM et al., 2020 [6]	30	0	8	NS	None	None	38	None	CS	Hysterectomy	NS
Inoue A et al., 2020 [7]	37	0	19	Yes	IVF	NRFS,FGR	36	None	CS	Hysterectomy	5860
Our case	29	0	2	none	none	none	39	Yes (Oxytocin)	CS	Hysterectomy	5400

Abbreviations: PSL predonisolone;GA,gestational age, IVF in vitro fertilization, CS cesarean section, GH gestational hypertension, PE preeclampsia, NRFS non-reassuring fetal status, FGR fetal growth restriction, NS not stated, SLE systemic lupus erythematosus, PAS placenta accrete spectrum